On the morning of January 16, among the two companies that broke through the scientific innovation board, Melander owed some luck and recorded the review result of “suspension of review”, which was also attributed to the non competition and confidentiality clauses.
Source: Official Website
Melander’s sponsor is Nanjing Securities Co.Ltd(601990) , with a financing amount of 574 million yuan. The company is mainly engaged in the business of related products in the field of pelvic floor and postpartum rehabilitation. The products mainly include pelvic floor and postpartum rehabilitation equipment, consumables and accessories, information products, etc. they are widely used in obstetrics and Gynecology, gynecology, pelvic floor rehabilitation center, confinement center, postpartum recovery center, mother and child center and other professional institutions in medical institutions. In the first three quarters of 2021, the operating revenue was 231 million yuan, and the net profit attributable to the shareholders of the parent company was 77.5431 million yuan.
According to the review, the regulators asked the company to implement whether the relevant non competition clauses signed by the actual controller in the history would lead to the instability of the company’s controlling right, and whether the relevant confidentiality clauses signed by the actual controller, core technicians and Nanjing Vishee Medical Technology Co.Ltd(688580) (688580. SH) would lead to the ownership dispute of the company’s core technology.
Judging from the instructions, mclande doesn’t describe much about the content of non competition. In terms of patents, as of the signing date of the specification, the company has 59 patents, including 8 invention patents, 32 utility models and 19 design patents.
As for patent dispute litigation, in fact, there have been many patent dispute litigation between meland and Nanjing Vishee Medical Technology Co.Ltd(688580) . The full name of Nanjing Vishee Medical Technology Co.Ltd(688580) is Nanjing Vishee Medical Technology Co.Ltd(688580) . It was founded in January 2001 with a registered capital of 68.3467 million yuan. It is mainly engaged in the R & D, production and sales of rehabilitation medical devices. It is committed to providing safe and effective rehabilitation medical products and overall solutions for medical and professional institutions in the subdivided fields of pelvic floor and postpartum rehabilitation, neurological rehabilitation and mental rehabilitation. The main products are electrical stimulation, magnetic stimulation Rehabilitation medical devices and products such as electrophysiological equipment, consumables and accessories. Nanjing Vishee Medical Technology Co.Ltd(688580) the operating revenue in the first half of 2021 was 191 million yuan, which was higher than that of Melander in the same period.
It can be seen from the sky eye check that the latest hearing information related to Mai Lunde and Nanjing Vishee Medical Technology Co.Ltd(688580) is September 9, 2020. The appellant is Mai Lunde and Nanjing Vishee Medical Technology Co.Ltd(688580) and the appellee is the State Intellectual Property Office; There was also a court hearing record on April 2, 2020. The plaintiff was Nanjing Vishee Medical Technology Co.Ltd(688580) , the defendant was the State Intellectual Property Office, and the third party was Melander. It should be pointed out that the core founding teams of Melander are all from Nanjing Vishee Medical Technology Co.Ltd(688580) .
Source: tianyancha
However, from the public information, although Melander did not have a lawsuit with Nanjing Vishee Medical Technology Co.Ltd(688580) recently, in August 2021, the company was sued by another Hangzhou Zhuowei Pharmaceutical Technology Co., Ltd. for contract dispute.
In addition to the above, the market has many concerns about McBride. First of all, the company has a single product structure. Its electrical stimulation equipment is the core sector, and the revenue of pelvic floor and postpartum rehabilitation equipment accounts for more than 70%. Secondly, its new business is generally at a loss. According to the instructions, in January 2017, mailunde established a subsidiary, ruishide, which is mainly engaged in the R & D and production of sports rehabilitation equipment. It has been operating for more than four years. By the end of 2020, the company had total assets of 5.41 million yuan and net assets of – 2.16 million yuan, which is in an insolvent state. In 2020, ruishide had a revenue of 7.65 million yuan and a net profit of only 105900 yuan.
In May 2018, mailunde established a subsidiary Yisu medical, which is mainly engaged in the R & D and production of female reproductive rehabilitation equipment and consumables. It has been in operation for three years. By the end of 2020, Yisu medical had total assets of 2.61 million yuan and net assets of 1.7 million yuan, operating income of 1.3 million yuan and loss of 290000 yuan in 2020. In 2019, Lianying medical, a subsidiary, was established, mainly engaged in the R & D and production of pelvic floor ultrasound images. At present, it is still in the R & D stage. By the end of 2020, the company had total assets of 2.22 million yuan, net assets of 1.85 million yuan, operating income of 0 million yuan and loss of 1.3337 million yuan in 2020. As for the mailunde Research Institute and maites engaged in the research and development of magnetic stimulation products, they have not been actually operated.
